Search

Displaying results 3091 - 3100 of 7540 in total
  1. Drug

    Dapoxetine

    go.drugbank.com/drugs/DB04884
    Investigational

    In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. … In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Basiliximab

    go.drugbank.com/drugs/DB00074
    ApprovedInvestigational

    known as CD25 antigen) on the surface of activated T-lymphocytes. … and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.

  3. Drug

    Bithionol

    go.drugbank.com/drugs/DB04813
    ApprovedWithdrawn

    Bithionol, formerly marketed as an active ingredient in various topical drug products, was shown to be a potent photosensitizer with the potential to cause serious skin disorders. … Approvals of the NDA's for bithionol drug products were withdrawn on October 24, 1967 (see the Federal Register of October 31, 1967 (32 FR 15046)).

  4. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration … [A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some success and include approved drugs such as

  5. Drug

    Rimexolone

    go.drugbank.com/drugs/DB00896
    ApprovedWithdrawn

    It is used to treat inflammation in the eye. It is marketed as Vexol.

  6. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    The mechanisms of its antimalarial effects are not well understood. … Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels.

    Categories: Analgesics, Non-Narcotic
  7. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  8. Drug

    Xenon-133

    go.drugbank.com/drugs/DB09315
    Approved

    Xenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.

  9. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … Immunohistochemical studies on pancreatic tissue also showed that NOX-700 therapy effectively preserved islet structure and increased insulin immunoreactivity.

  10. Drug

    Chlorphentermine

    go.drugbank.com/drugs/DB01556
    ApprovedIllicitWithdrawn

    It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1223)

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome